| KALV Stock | | | USD 11.89 0.11 0.92% |
Director
Stephen Donnelly is Director Secretary of Kalvista Pharmaceuticals
| Address | 55 Cambridge Parkway, Cambridge, MA, United States, 02142 |
| Phone | 857 999 0075 |
| Web | https://www.kalvista.com |
Kalvista Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.5815) % which means that it has lost $0.5815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.505) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals'
Return On Capital Employed is fairly stable compared to the past year.
Return On Equity is likely to climb to 0.17 in 2025, despite the fact that
Return On Tangible Assets are likely to grow to
(1.03). At this time, Kalvista Pharmaceuticals'
Total Assets are fairly stable compared to the past year.
Non Current Assets Total is likely to climb to about 11.7
M in 2025, despite the fact that
Return On Tangible Assets are likely to grow to
(1.03).
Kalvista Pharmaceuticals currently holds 7.32
M in liabilities with Debt to Equity
(D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Kalvista Pharmaceuticals has a current ratio of 17.16, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Kalvista Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | DIRECTOR Age |
| David JD | Kronos Bio | 54 |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. Kalvista Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. Kalvista Pharmaceuticals (KALV) is traded on NASDAQ Exchange in USA. It is located in 55 Cambridge Parkway, Cambridge, MA, United States, 02142 and employs 150 people. Kalvista Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Kalvista Pharmaceuticals Leadership Team
Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jarrod Aldom, Vice Communications | |
| Nicole Sweeny, Chief Officer | |
| Ryan Baker, Head Relations | |
| Benjamin Palleiko, Chief President | |
| Brian Piekos, Chief Officer | |
| John McKune, VP Fin | |
| Thomas MBA, CEO Director | |
| Michael PharmD, Senior Development | |
| Christopher Yea, Chief Development Officer | |
| MD MBA, Chief Officer | |
| Jeb Ledell, Chief Officer | |
| Stephen Donnelly, Director Secretary | |
| Rachel Morten, Senior QA | |
| Edward Feener, Chief Scientific Officer | |
| Brian JD, General Counsel | |
Kalvista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to
measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.